{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:37:30Z","timestamp":1792179450040,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04442-2","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:04:18Z","timestamp":1780391058000},"page":"2546-2555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Lukas","family":"Bethlehem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Bartu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Marke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Eggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-1223","authenticated-orcid":false,"given":"Graham J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5499-7745","authenticated-orcid":false,"given":"Varun","family":"Aggarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Bongers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Mogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-4500","authenticated-orcid":false,"given":"Jeremiah J.","family":"Faith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-1538","authenticated-orcid":false,"given":"Ari","family":"Grinspan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"4442_CR1","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna, S. et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs 82, 1527\u20131538 (2022).","journal-title":"Drugs"},{"key":"4442_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt, P. et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N. Engl. J. Med. 386, 220\u2013229 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4442_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1205037","volume":"368","author":"E van Nood","year":"2013","unstructured":"van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407\u2013415 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4442_CR4","doi-asserted-by":"publisher","first-page":"1985\u22121993","DOI":"10.1001\/jama.2017.17077","volume":"318","author":"D Kao","year":"2017","unstructured":"Kao, D. et al. Effect of oral capsule\u2013 vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 318, 1985\u22121993 (2017).","journal-title":"JAMA"},{"key":"4442_CR5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/ibd\/izaa283","volume":"27","author":"JR Allegretti","year":"2021","unstructured":"Allegretti, J. R. et al. Inflammatory bowel disease outcomes following fecal microbiota transplantation for recurrent C. difficile infection. Inflamm. Bowel Dis. 27, 1371\u20131378 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"4442_CR6","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1001\/jama.2014.13875","volume":"312","author":"I Youngster","year":"2014","unstructured":"Youngster, I. et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312, 1772\u20131778 (2014).","journal-title":"JAMA"},{"key":"4442_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41586-024-08242-x","volume":"637","author":"A Chen-Liaw","year":"2024","unstructured":"Chen-Liaw, A. et al. Gut microbiota strain richness is species specific and affects engraftment. Nature 637, 422\u2013429 (2024).","journal-title":"Nature"},{"key":"4442_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41564-021-00966-0","volume":"6","author":"V Aggarwala","year":"2021","unstructured":"Aggarwala, V. et al. Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nat. Microbiol. 6, 1309\u20131318 (2021).","journal-title":"Nat. Microbiol."},{"key":"4442_CR9","doi-asserted-by":"publisher","unstructured":"Faith, J. J. et al. Strain population structure varies widely across bacterial species and predicts strain colonization in unrelated individuals. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.10.17.343640 (2020).","DOI":"10.1101\/2020.10.17.343640"},{"key":"4442_CR10","doi-asserted-by":"publisher","first-page":"130848","DOI":"10.1172\/jci.insight.130848","volume":"4","author":"JL Drewes","year":"2019","unstructured":"Drewes, J. L. et al. Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile. JCI Insight 4, 130848 (2019).","journal-title":"JCI Insight"},{"key":"4442_CR11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043\u20132050 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4442_CR12","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1093\/cid\/ciaa1486","volume":"72","author":"C Zellmer","year":"2021","unstructured":"Zellmer, C. et al. Shiga toxin-producing Escherichia coli transmission via fecal microbiota transplant. Clin Infect Dis 72, e876\u2013e880 (2021).","journal-title":"Clin Infect Dis"},{"key":"4442_CR13","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jama.2023.4314","volume":"329","author":"T Louie","year":"2023","unstructured":"Louie, T. et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA 329, 1356\u20131366 (2023).","journal-title":"JAMA"},{"key":"4442_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/apt.16309","volume":"53","author":"AA Rode","year":"2021","unstructured":"Rode, A. A. et al. Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Aliment. Pharmacol. Ther. 53, 999\u20131009 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4442_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(21)00007-8","volume":"6","author":"D Kao","year":"2021","unstructured":"Kao, D. et al. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol. Hepatol. 6, 282\u2013291 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"4442_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/2049-2618-1-3","volume":"1","author":"EO Petrof","year":"2013","unstructured":"Petrof, E. O. et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: \u2018RePOOPulating\u2019 the gut. Microbiome 1, 3 (2013).","journal-title":"Microbiome"},{"key":"4442_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S0140-6736(89)92749-9","volume":"1","author":"M Tvede","year":"1989","unstructured":"Tvede, M. & Rask-Madsen, J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1, 1156\u20131160 (1989).","journal-title":"Lancet"},{"key":"4442_CR18","doi-asserted-by":"publisher","first-page":"657320","DOI":"10.3389\/fcimb.2021.657320","volume":"11","author":"A Varga","year":"2021","unstructured":"Varga, A. et al. How to apply FMT more effectively, conveniently and flexible\u2014a comparison of FMT methods. Front. Cell. Infect. Microbiol. 11, 657320 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"4442_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.cmi.2017.05.015","volume":"23","author":"EM Terveer","year":"2017","unstructured":"Terveer, E. M. et al. How to: establish and run a stool bank. Clin. Microbiol. Infect. 23, 924\u2013930 (2017).","journal-title":"Clin. Microbiol. Infect."},{"key":"4442_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2013.09.060","volume":"12","author":"CR Kelly","year":"2014","unstructured":"Kelly, C. R., Kunde, S. S. & Khoruts, A. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin. Gastroenterol. Hepatol. 12, 283\u2013288 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4442_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ibd\/izy398","volume":"25","author":"RP Hirten","year":"2019","unstructured":"Hirten, R. P. et al. Microbial engraftment and efficacy of fecal microbiota transplant for Clostridium difficile in patients with and without inflammatory bowel disease. Inflamm. Bowel Dis. 25, 969\u2013979 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"4442_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","volume":"28","author":"G Ianiro","year":"2022","unstructured":"Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med. 28, 1913\u20131923 (2022).","journal-title":"Nat. Med."},{"key":"4442_CR23","doi-asserted-by":"publisher","first-page":"2520412","DOI":"10.1080\/19490976.2025.2520412","volume":"17","author":"J Claypool","year":"2025","unstructured":"Claypool, J. et al. Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection. Gut Microbes 17, 2520412 (2025).","journal-title":"Gut Microbes"},{"key":"4442_CR24","doi-asserted-by":"publisher","first-page":"e00893","DOI":"10.1128\/mBio.00893-14","volume":"5","author":"AM Seekatz","year":"2014","unstructured":"Seekatz, A. M. et al. Recovery of the gut microbiome following fecal microbiota transplantation. mBio 5, e00893\u201300814 (2014).","journal-title":"mBio"},{"key":"4442_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4161\/gmic.23571","volume":"4","author":"MJ Hamilton","year":"2013","unstructured":"Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A. & Sadowsky, M. J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4, 125\u2013135 (2013).","journal-title":"Gut Microbes"},{"key":"4442_CR26","unstructured":"Fecal microbiota for transplantation: safety alert \u2212 risk of serious adverse events likely due to transmission of pathogenic organisms. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission (US Food and Drug Administration, 2020)."},{"key":"4442_CR27","unstructured":"Fecal microbiota for transplantation: safety communication \u2212 risk of serious adverse reactions due to transmission of multi-drug resistant organisms. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fecal-microbiota-transplantation-safety-communication-risk-serious-adverse-reactions-due (US Food and Drug Administration, 2019)."},{"key":"4442_CR28","doi-asserted-by":"publisher","first-page":"e20232055","DOI":"10.1084\/jem.20232055","volume":"222","author":"TD Kellogg","year":"2025","unstructured":"Kellogg, T. D. et al. Succinate-producing microbiota drives tuft cell hyperplasia to protect against Clostridioides difficile. J. Exp. Med. 222, e20232055 (2025).","journal-title":"J. Exp. Med."},{"key":"4442_CR29","unstructured":"Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information: guidance for industry. https:\/\/www.fda.gov\/files\/vaccines,%20blood%20%26%20biologics\/published\/Early-Clinical-Trials-With-Live-Biotherapeutic-Products--Chemistry--Manufacturing--and-Control-Information--Guidance-for-Industry.pdf (US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2016)."},{"key":"4442_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00535-021-01822-y","volume":"57","author":"J El Halabi","year":"2022","unstructured":"El Halabi, J., Palmer, N., Fox, K., Kohane, I. & Farhat, M. R. Fecal microbiota transplantation and Clostridioides difficile infection among privately insured patients in the United States. J. Gastroenterol. 57, 10\u201318 (2022).","journal-title":"J. Gastroenterol."},{"key":"4442_CR31","doi-asserted-by":"publisher","first-page":"103302","DOI":"10.1016\/j.eclinm.2025.103302","volume":"85","author":"SE Paaske","year":"2025","unstructured":"Paaske, S. E. et al. Clinical management of Clostridioides difficile infection with faecal microbiota transplantation: a real-world cohort study. EClinicalMedicine 85, 103302 (2025).","journal-title":"EClinicalMedicine"},{"key":"4442_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/MCG.0000000000001667","volume":"57","author":"A Beran","year":"2023","unstructured":"Beran, A. et al. Predictors of fecal microbiota transplant failure in Clostridioides difficile infection: an updated meta-analysis. J. Clin. Gastroenterol. 57, 389\u2013399 (2023).","journal-title":"J. Clin. Gastroenterol."},{"key":"4442_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery, A. F. et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology 166, 409\u2013434 (2024).","journal-title":"Gastroenterology"},{"key":"4442_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.09.030","volume":"168","author":"JR Allegretti","year":"2025","unstructured":"Allegretti, J. R. et al. Safety and tolerability of CP101, a full-spectrum, oral microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection: a phase 2 randomized controlled trial. Gastroenterology 168, 357\u2013366 (2025).","journal-title":"Gastroenterology"},{"key":"4442_CR35","doi-asserted-by":"crossref","unstructured":"Kao, D. et al. Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial. Lancet Gastroenterol. Hepatol. 10, 986\u2212997 (2025).","DOI":"10.1016\/S2468-1253(25)00190-6"},{"key":"4442_CR36","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","volume":"41","author":"A Blanco-M\u00edguez","year":"2023","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633\u20131644 (2023).","journal-title":"Nat. Biotechnol."},{"key":"4442_CR37","unstructured":"Blaser, M. J. Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues (Holt, 2014)."},{"key":"4442_CR38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","volume":"30","author":"M Dsouza","year":"2022","unstructured":"Dsouza, M. et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe 30, 583\u2013598 (2022).","journal-title":"Cell Host Microbe"},{"key":"4442_CR39","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","volume":"14","author":"IC Glitza","year":"2024","unstructured":"Glitza, I. C. et al. Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discov. 14, 1161\u20131175 (2024).","journal-title":"Cancer Discov."},{"key":"4442_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-022-05620-1","volume":"614","author":"M Valles-Colomer","year":"2023","unstructured":"Valles-Colomer, M. et al. The person-to-person transmission landscape of the gut and oral microbiomes. Nature 614, 125\u2013135 (2023).","journal-title":"Nature"},{"key":"4442_CR41","doi-asserted-by":"publisher","first-page":"2447836","DOI":"10.1080\/19490976.2024.2447836","volume":"17","author":"JJ Faith","year":"2025","unstructured":"Faith, J. J. Assessing live microbial therapeutic transmission. Gut Microbes 17, 2447836 (2025).","journal-title":"Gut Microbes"},{"key":"4442_CR42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41587-020-00797-0","volume":"39","author":"MR Olm","year":"2021","unstructured":"Olm, M. R. et al. inStrain profiles population microdiversity from metagenomic data and sensitively detects shared microbial strains. Nat. Biotechnol. 39, 727\u2013736 (2021).","journal-title":"Nat. Biotechnol."},{"key":"4442_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.chom.2018.01.003","volume":"23","author":"CS Smillie","year":"2018","unstructured":"Smillie, C. S. et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23, 229\u2013240 (2018).","journal-title":"Cell Host Microbe"},{"key":"4442_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41579-021-00667-9","volume":"20","author":"MT Sorbara","year":"2022","unstructured":"Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. Nat. Rev. Microbiol. 20, 365\u2013380 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"4442_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nature13828","volume":"517","author":"CG Buffie","year":"2015","unstructured":"Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205\u2013208 (2015).","journal-title":"Nature"},{"key":"4442_CR46","doi-asserted-by":"publisher","first-page":"e1002995","DOI":"10.1371\/journal.ppat.1002995","volume":"8","author":"TD Lawley","year":"2012","unstructured":"Lawley, T. D. et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8, e1002995 (2012).","journal-title":"PLoS Pathog."},{"key":"4442_CR47","doi-asserted-by":"publisher","first-page":"eaam7019","DOI":"10.1126\/scitranslmed.aam7019","volume":"10","author":"EJ Battaglioli","year":"2018","unstructured":"Battaglioli, E. J. et al. Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. Sci. Transl. Med. 10, eaam7019 (2018).","journal-title":"Sci. Transl. Med."},{"key":"4442_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545\u2013556 (2022).","journal-title":"Nat. Med."},{"key":"4442_CR49","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.chom.2024.08.004","volume":"32","author":"E Hayase","year":"2024","unstructured":"Hayase, E. et al. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe 32, 1621\u20131636 (2024).","journal-title":"Cell Host Microbe"},{"key":"4442_CR50","doi-asserted-by":"publisher","first-page":"2374954","DOI":"10.1080\/2162402X.2024.2374954","volume":"13","author":"M Bredon","year":"2024","unstructured":"Bredon, M. et al. Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 13, 2374954 (2024).","journal-title":"Oncoimmunology"},{"key":"4442_CR51","doi-asserted-by":"publisher","first-page":"e0079724","DOI":"10.1128\/msphere.00797-24","volume":"10","author":"AM Seekatz","year":"2025","unstructured":"Seekatz, A. M. Straining to define a healthy microbiome. mSphere 10, e0079724 (2025).","journal-title":"mSphere"},{"key":"4442_CR52","doi-asserted-by":"publisher","first-page":"e00045","DOI":"10.1128\/mSphere.00045-15","volume":"1","author":"CM Theriot","year":"2016","unstructured":"Theriot, C. M., Bowman, A. A. & Young, V. B. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere 1, e00045\u201315 (2016).","journal-title":"mSphere"},{"key":"4442_CR53","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41586-022-05438-x","volume":"611","author":"AB Smith","year":"2022","unstructured":"Smith, A. B. et al. Enterococci enhance Clostridioides difficile pathogenesis. Nature 611, 780\u2013786 (2022).","journal-title":"Nature"},{"key":"4442_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102\u2013109 (2015).","journal-title":"Gastroenterology"},{"key":"4442_CR55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","volume":"149","author":"NG Rossen","year":"2015","unstructured":"Rossen, N. G. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110\u2013118 (2015).","journal-title":"Gastroenterology"},{"key":"4442_CR56","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","volume":"389","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218\u20131228 (2017).","journal-title":"Lancet"},{"key":"4442_CR57","doi-asserted-by":"crossref","unstructured":"Gogokhia, L. et al. Donor composition and fiber promote strain engraftment in a randomized controlled trial of fecal microbiota transplant for ulcerative colitis. Med 6, 100707 (2025).","DOI":"10.1016\/j.medj.2025.100707"},{"key":"4442_CR58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","volume":"321","author":"SP Costello","year":"2019","unstructured":"Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156\u2013164 (2019).","journal-title":"JAMA"},{"key":"4442_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","volume":"7","author":"C Haifer","year":"2022","unstructured":"Haifer, C. et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol. Hepatol. 7, 141\u2013151 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"4442_CR60","doi-asserted-by":"publisher","first-page":"21536","DOI":"10.1073\/pnas.1922189117","volume":"117","author":"GJ Britton","year":"2020","unstructured":"Britton, G. J. et al. Defined microbiota transplant restores Th17\/ROR\u03b3t+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proc. Natl Acad. Sci. USA 117, 21536\u201321545 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4442_CR61","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/bioinformatics\/btu153","volume":"30","author":"T Seemann","year":"2014","unstructured":"Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068\u20132069 (2014).","journal-title":"Bioinformatics"},{"key":"4442_CR62","doi-asserted-by":"publisher","first-page":"D690","DOI":"10.1093\/nar\/gkac920","volume":"51","author":"BP Alcock","year":"2023","unstructured":"Alcock, B. P. et al. CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res. 51, D690\u2013D699 (2023).","journal-title":"Nucleic Acids Res."},{"key":"4442_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403\u2013410 (1990).","journal-title":"J. Mol. Biol."},{"key":"4442_CR64","doi-asserted-by":"publisher","first-page":"D678","DOI":"10.1093\/nar\/gkac1003","volume":"51","author":"RD Olson","year":"2023","unstructured":"Olson, R. D. et al. Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR. Nucleic Acids Res. 51, D678\u2013D689 (2023).","journal-title":"Nucleic Acids Res."},{"key":"4442_CR65","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1093\/bioinformatics\/bty095","volume":"34","author":"C Bertelli","year":"2018","unstructured":"Bertelli, C. & Brinkman, F. S. L. Improved genomic island predictions with IslandPath-DIMOB. Bioinformatics 34, 2161\u20132167 (2018).","journal-title":"Bioinformatics"},{"key":"4442_CR66","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1007\/s00253-023-12558-5","volume":"107","author":"MP Coryell","year":"2023","unstructured":"Coryell, M. P., Sava, R. L., Hastie, J. L. & Carlson, P. E. Application of MALDI-TOF MS for enumerating bacterial constituents of defined consortia. Appl. Microbiol. Biotechnol. 107, 4069\u20134077 (2023).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"4442_CR67","unstructured":"Aggarwala, V., Watson A. & Faith, J. strainer2. GitHub https:\/\/github.com\/jeremiahfaith\/strainer2 (2023)."},{"key":"4442_CR68","doi-asserted-by":"publisher","first-page":"e70078","DOI":"10.1002\/imt2.70078","volume":"4","author":"S Chen","year":"2025","unstructured":"Chen, S. fastp 1.0: An ultra-fast all-round tool for FASTQ data quality control and preprocessing. Imeta 4, e70078 (2025).","journal-title":"Imeta"},{"key":"4442_CR69","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41592-025-02981-z","volume":"23","author":"M Aton","year":"2026","unstructured":"Aton, M. et al. Scikit-bio: a fundamental Python library for biological omic data analysis. Nat. Methods 23, 274\u2013276 (2026).","journal-title":"Nat. Methods"},{"key":"4442_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates, D., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Soft. 67, 1\u201348 (2015).","journal-title":"J. Stat. Soft."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04442-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:18Z","timestamp":1784210538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04442-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4442"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04442-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.F. is on the scientific advisory board of Vedanta Biosciences, reports receiving research grants from Janssen Pharmaceuticals and reports receiving consulting fees from GENFIT and Vedanta Biosciences. A patent is filed on MTC01 (J.J.F., L. Bethlehem, J.E. and V.A.). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}